AMG 232 + trametinib + dabrafenib

AMG 232 + trametinib + dabrafenib is a combination investigational regimen for metastatic melanoma, especially in tumors with wild-type TP53 and/or BRAF V600 mutations. AMG 232 is an oral, small molecule inhibitor targeting the MDM2-p53 protein interaction, thereby activating the tumor suppressor p53 pathway and resulting in cell cycle arrest or apoptosis in cancer cells with functional TP53. Trametinib is a MEK inhibitor, and dabrafenib is a BRAF inhibitor; both target the MAPK/ERK pathway, which is commonly dysregulated in melanoma. Together, these agents were tested in dose-escalation trials for synergistic activity in metastatic melanoma, but further clinical development of AMG 232 was discontinued after phase 1/2a due to toxicity profile and lack of significant added clinical benefit beyond the MAPK inhibitors alone[1][2][3][4].